These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 29032767)

  • 1. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
    Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
    BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted
    Notararigo S; Martín-Pastor M; Viñuela-Roldán JE; Quiroga A; Dominguez-Munoz JE; Barreiro-de Acosta M
    J Mol Med (Berl); 2021 Sep; 99(9):1251-1264. PubMed ID: 34021361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment.
    Di Sabatino A; Santilli F; Guerci M; Simeone P; Ardizzone S; Massari A; Giuffrida P; Tripaldi R; Malara A; Liani R; Gurini E; Aronico N; Balduini A; Corazza GR; Davì G
    Thromb Haemost; 2016 Aug; 116(3):486-95. PubMed ID: 27305860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
    Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
    Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
    Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
    Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases.
    Ungar B; Glidai Y; Yavzori M; Picard O; Fudim E; Lahad A; Haberman Y; Shouval DS; Weintraub I; Eliakim R; Ben-Horin S; Weiss B
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):507-512. PubMed ID: 29901557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
    Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
    Veerappan SG; Healy M; Walsh B; O'Morain CA; Daly JS; Ryan BM
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1335-44. PubMed ID: 27508327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals.
    Bjerrum JT; Wang Y; Hao F; Coskun M; Ludwig C; Günther U; Nielsen OH
    Metabolomics; 2015; 11():122-133. PubMed ID: 25598765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases.
    Dawiskiba T; Deja S; Mulak A; Ząbek A; Jawień E; Pawełka D; Banasik M; Mastalerz-Migas A; Balcerzak W; Kaliszewski K; Skóra J; Barć P; Korta K; Pormańczuk K; Szyber P; Litarski A; Młynarz P
    World J Gastroenterol; 2014 Jan; 20(1):163-74. PubMed ID: 24415869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
    Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
    Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.
    Bravo F; Macpherson JA; Slack E; Patuto N; Cahenzli J; McCoy KD; Macpherson AJ; Juillerat P;
    Clin Transl Gastroenterol; 2021 Feb; 12(2):e00298. PubMed ID: 33735154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
    Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT.
    Kampa KC; Morsoletto DBG; Loures MR; Pissaia A; Nones RB; Ivantes CAP
    Arq Gastroenterol; 2017 Dec; 54(4):333-337. PubMed ID: 28954041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.